You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBromfenac
Accession NumberDB00963  (APRD00831)
TypeSmall Molecule
GroupsApproved
DescriptionBromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool to optimize surgical outcomes.
Structure
Thumb
Synonyms
[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid
2-amino-3-(4-Bromobenzoyl)benzeneacetic acid
Bromfenaco
Bromfenacum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bromdaysolution/ drops.9 mg/mLophthalmicUnit Dose Services2010-09-20Not applicableUs
Bromdaysolution/ drops.9 mg/mLophthalmicPhysicians Total Care, Inc.2011-09-30Not applicableUs
Bromdaysolution/ drops.9 mg/mLophthalmicIsta Pharmaceuticals, Inc2010-09-20Not applicableUs
Prolensasolution/ drops.7 mg/mLophthalmicBausch & Lomb Incorporated2013-04-08Not applicableUs
Prolensasolution0.07 %ophthalmicBausch & Lomb Inc2015-09-25Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bromfenacsolution/ drops.9 mg/mLophthalmicMylan Pharmaceuticals, Inc.2011-05-11Not applicableUs
Bromfenacsolution/ drops1.035 mg/mLophthalmicPhysicians Total Care, Inc.2012-04-13Not applicableUs
Bromfenacsolution/ drops.9 mg/mLophthalmicMylan Pharmaceuticals, Inc.2011-05-11Not applicableUs
Bromfenacsolution/ drops.9 mg/mLophthalmicMylan Pharmaceuticals, Inc.2011-05-11Not applicableUs
Bromfenacsolution/ drops.9 mg/mLophthalmicApotex Corp2014-06-19Not applicableUs
Bromfenacsolution/ drops1.035 mg/mLophthalmicHi Tech Pharmacal Co., Inc.2014-01-22Not applicableUs
Bromfenac Ophthalmic Solution, 0.09%solution/ drops1.035 mg/mLophthalmicApotex Corp.2014-06-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DuractWyeth-Ayerst
XibromISTA Pharmaceuticals
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bromfenac sodium
120638-55-3
Thumb
  • InChI Key: PPOSVVJOVKVBPW-UHFFFAOYSA-L
  • Monoisotopic Mass: 763.995695148
  • Average Mass: 766.339
DBSALT000356
Categories
UNII864P0921DW
CAS number91714-94-2
WeightAverage: 334.165
Monoisotopic: 333.000055902
Chemical FormulaC15H12BrNO3
InChI KeyInChIKey=ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
InChI
InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
IUPAC Name
2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
SMILES
NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • Phenylacetate
  • Acetophenone
  • Substituted aniline
  • Aryl ketone
  • Benzoyl
  • Halobenzene
  • Bromobenzene
  • Aniline
  • Primary aromatic amine
  • Aryl halide
  • Aryl bromide
  • Vinylogous amide
  • Ketone
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of postoperative inflammation in patients who have undergone cataract extraction.
PharmacodynamicsBromfenac ophthalmic solution is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use.
Mechanism of actionThe mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Related Articles
AbsorptionThe plasma concentration of bromfenac following ocular administration in humans is unknown.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bromfenac Action PathwayDrug actionSMP00102
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9133
Blood Brain Barrier+0.8403
Caco-2 permeable+0.5999
P-glycoprotein substrateNon-substrate0.7803
P-glycoprotein inhibitor INon-inhibitor0.663
P-glycoprotein inhibitor IINon-inhibitor0.8983
Renal organic cation transporterNon-inhibitor0.921
CYP450 2C9 substrateNon-substrate0.8624
CYP450 2D6 substrateNon-substrate0.898
CYP450 3A4 substrateNon-substrate0.7483
CYP450 1A2 substrateNon-inhibitor0.7326
CYP450 2C9 inhibitorNon-inhibitor0.6515
CYP450 2D6 inhibitorNon-inhibitor0.9003
CYP450 2C19 inhibitorNon-inhibitor0.8688
CYP450 3A4 inhibitorNon-inhibitor0.8927
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7996
Ames testNon AMES toxic0.88
CarcinogenicityNon-carcinogens0.7301
BiodegradationNot ready biodegradable0.9618
Rat acute toxicity2.5564 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9747
hERG inhibition (predictor II)Non-inhibitor0.8313
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ista pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Solution/ dropsophthalmic.9 mg/mL
Solution/ dropsophthalmic1.035 mg/mL
Solutionophthalmic0.07 %
Solution/ dropsophthalmic.7 mg/mL
Prices
Unit descriptionCostUnit
Xibrom 0.09% Solution 5ml Bottle289.59USD bottle
Xibrom 0.09% Solution 2.5ml Bottle148.56USD bottle
Xibrom 0.09% eye drops68.57USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8129431 No2005-09-112025-09-11Us
US8669290 No2004-01-162024-01-16Us
US8754131 No2004-01-162024-01-16Us
US8778999 No2009-09-032029-09-03Us
US8871813 No2004-01-162024-01-16Us
US8927606 No2004-01-162024-01-16Us
US9144609 No2004-01-162024-01-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0126 mg/mLALOGPS
logP3ALOGPS
logP3.66ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)3.81ChemAxon
pKa (Strongest Basic)1.59ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.39 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity80.26 m3·mol-1ChemAxon
Polarizability29.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Shirou Sawa, “Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac.” U.S. Patent US20070082857, issued April 12, 2007.

US20070082857
General ReferencesNot Available
External Links
ATC CodesS01BC11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (41.5 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabBromfenac may increase the anticoagulant activities of Abciximab.
AcebutololBromfenac may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aceclofenac.
AcenocoumarolBromfenac may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bromfenac.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Bromfenac.
Alendronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alendronic acid.
AliskirenBromfenac may decrease the antihypertensive activities of Aliskiren.
AlprenololBromfenac may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Bromfenac.
AmikacinBromfenac may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideBromfenac may decrease the antihypertensive activities of Amiloride.
AncrodBromfenac may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Antipyrine.
Antithrombin III humanBromfenac may increase the anticoagulant activities of Antithrombin III human.
ApixabanBromfenac may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Bromfenac is combined with Apremilast.
ArdeparinBromfenac may increase the anticoagulant activities of Ardeparin.
ArgatrobanBromfenac may increase the anticoagulant activities of Argatroban.
ArotinololBromfenac may decrease the antihypertensive activities of Arotinolol.
AtenololBromfenac may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bromfenac.
BalsalazideBromfenac may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Bromfenac.
BecaplerminBromfenac may increase the anticoagulant activities of Becaplermin.
BefunololBromfenac may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bromfenac.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bromfenac.
BenoxaprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Benoxaprofen.
BetaxololBromfenac may decrease the antihypertensive activities of Betaxolol.
BevantololBromfenac may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Bromfenac.
BisoprololBromfenac may decrease the antihypertensive activities of Bisoprolol.
BivalirudinBromfenac may increase the anticoagulant activities of Bivalirudin.
BopindololBromfenac may decrease the antihypertensive activities of Bopindolol.
BufuralolBromfenac may decrease the antihypertensive activities of Bufuralol.
BumetanideBromfenac may decrease the diuretic activities of Bumetanide.
BupranololBromfenac may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bromfenac.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Bromfenac.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Bromfenac.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Bromfenac.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Bromfenac.
CarteololBromfenac may decrease the antihypertensive activities of Carteolol.
CarvedilolBromfenac may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Bromfenac.
CeliprololBromfenac may decrease the antihypertensive activities of Celiprolol.
CertoparinBromfenac may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bromfenac.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bromfenac.
CholestyramineCholestyramine can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bromfenac.
Citric AcidBromfenac may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Bromfenac.
ColesevelamColesevelam can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineBromfenac may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Bromfenac is combined with D-Limonene.
Dabigatran etexilateBromfenac may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinBromfenac may increase the anticoagulant activities of Dalteparin.
DanaparoidBromfenac may increase the anticoagulant activities of Danaparoid.
DaunorubicinBromfenac may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Bromfenac is combined with Deferasirox.
DesirudinBromfenac may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bromfenac.
DextranBromfenac may increase the anticoagulant activities of Dextran.
Dextran 40Bromfenac may increase the anticoagulant activities of Dextran 40.
Dextran 70Bromfenac may increase the anticoagulant activities of Dextran 70.
Dextran 75Bromfenac may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bromfenac.
DicoumarolBromfenac may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bromfenac.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bromfenac.
DihydrostreptomycinBromfenac may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Bromfenac.
DoxorubicinBromfenac may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneBromfenac may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Droxicam.
Edetic AcidBromfenac may increase the anticoagulant activities of Edetic Acid.
EdoxabanBromfenac may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Bromfenac.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bromfenac.
EnoxaparinBromfenac may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Bromfenac is combined with Epirizole.
EpirubicinBromfenac may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneBromfenac may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bromfenac.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromfenac.
EsmololBromfenac may decrease the antihypertensive activities of Esmolol.
Etacrynic acidBromfenac may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Bromfenac.
Ethyl biscoumacetateBromfenac may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Bromfenac.
EtofenamateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Bromfenac is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Bromfenac.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bromfenac.
FlunixinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bromfenac.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bromfenac.
Fondaparinux sodiumBromfenac may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Bromfenac.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bromfenac.
FramycetinBromfenac may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideBromfenac may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Bromfenac.
GentamicinBromfenac may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Haloperidol.
HeparinBromfenac may increase the anticoagulant activities of Heparin.
HirulogBromfenac may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Bromfenac is combined with HMPL-004.
HydralazineBromfenac may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bromfenac.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bromfenac.
Hygromycin BBromfenac may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Bromfenac is combined with Icatibant.
IdarubicinBromfenac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bromfenac.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bromfenac.
IndenololBromfenac may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bromfenac.
IndoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromfenac.
IsoxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Isoxicam.
KanamycinBromfenac may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Bromfenac.
LabetalolBromfenac may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Leflunomide.
LepirudinBromfenac may increase the anticoagulant activities of Lepirudin.
LevobunololBromfenac may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bromfenac.
LithiumThe serum concentration of Lithium can be increased when it is combined with Bromfenac.
LornoxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Bromfenac.
LoxoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Bromfenac.
LumiracoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bromfenac.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bromfenac.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bromfenac.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bromfenac.
MesalazineBromfenac may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Bromfenac.
MetamizoleThe risk or severity of adverse effects can be increased when Bromfenac is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bromfenac.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bromfenac.
MetipranololBromfenac may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac.
MetoprololBromfenac may decrease the antihypertensive activities of Metoprolol.
MetrizamideBromfenac may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bromfenac.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Bromfenac.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bromfenac.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bromfenac.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Bromfenac.
NadololBromfenac may decrease the antihypertensive activities of Nadolol.
NadroparinBromfenac may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bromfenac.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Bromfenac.
NCX 4016The risk or severity of adverse effects can be increased when Bromfenac is combined with NCX 4016.
NeomycinBromfenac may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nepafenac.
NetilmicinBromfenac may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bromfenac.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromfenac.
OlsalazineBromfenac may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bromfenac.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Bromfenac.
OrgoteinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Orgotein.
OtamixabanBromfenac may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxaprozin.
OxprenololBromfenac may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Parecoxib.
ParomomycinBromfenac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololBromfenac may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateBromfenac may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Bromfenac.
PhenindioneBromfenac may increase the anticoagulant activities of Phenindione.
PhenprocoumonBromfenac may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bromfenac.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bromfenac.
PindololBromfenac may decrease the antihypertensive activities of Pindolol.
PiretanideBromfenac may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bromfenac.
PlicamycinBromfenac may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bromfenac.
PractololBromfenac may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Bromfenac.
ProbenecidThe serum concentration of Bromfenac can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Propacetamol.
PropranololBromfenac may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Bromfenac.
Protein CBromfenac may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeBromfenac may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Bromfenac is combined with PTC299.
PuromycinBromfenac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Bromfenac.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bromfenac.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bromfenac.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bromfenac.
ResveratrolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.
ReviparinBromfenac may increase the anticoagulant activities of Reviparin.
RibostamycinBromfenac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Risedronate.
RivaroxabanBromfenac may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Bromfenac.
SalicylamideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bromfenac.
SalsalateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bromfenac.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Bromfenac.
SeratrodastThe risk or severity of adverse effects can be increased when Bromfenac is combined with Seratrodast.
SotalolBromfenac may decrease the antihypertensive activities of Sotalol.
SpectinomycinBromfenac may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Bromfenac.
SpironolactoneBromfenac may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Bromfenac is combined with SRT501.
StreptomycinBromfenac may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinBromfenac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineBromfenac may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bromfenac.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bromfenac.
SulodexideBromfenac may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Bromfenac.
TacrolimusBromfenac may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Bromfenac.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Bromfenac.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bromfenac.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Bromfenac.
TenofovirThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Bromfenac.
TepoxalinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiludronate.
TimololBromfenac may decrease the antihypertensive activities of Timolol.
TobramycinBromfenac may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bromfenac.
TorasemideBromfenac may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bromfenac.
TranilastThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bromfenac.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bromfenac.
TriamtereneBromfenac may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bromfenac.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Bromfenac.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromfenac.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Bromfenac.
WarfarinBromfenac may increase the anticoagulant activities of Warfarin.
XimelagatranBromfenac may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Bromfenac.
Zoledronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [PubMed:16846546 ]
  2. Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S: Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32. [PubMed:16982289 ]
  3. Chitturi S, George J: Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22(2):169-83. [PubMed:12016548 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [PubMed:16846546 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Cho H, Wolf KJ, Wolf EJ: Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol. 2009;3:199-210. Epub 2009 Jun 2. [PubMed:19668566 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:23